Airway responses and inflammation in subjects with asthma after four days of repeated high-single-dose allergen challenge

Respiratory Research

Ralf Schubert¹  Stefan Zielen¹  Markus A Rose¹  Ulrich Zissler¹  Sandra Voss¹  Johannes Schulze¹ 

[1] Department of Allergy, Pulmonology, and Cystic Fibrosis, Children's Hospital, Goethe-University, Frankfurt, Germany

关键词: Foxp3;    IFN-γ;    IL-8;    IL-5;    Eosinophils;    Exhaled NO;    Bronchial hyperresponsiveness;    Bronchial allergen challenge;   

Others  :  796657
DOI  :  10.1186/1465-9921-13-78

 received in 2011-11-24, accepted in 2012-06-27,  发布年份 2012

【 摘 要 】

Background

Both standard and low-dose allergen provocations are an established tool in asthma research to improve our understanding of the pathophysiological mechanism of allergic asthma. However, clinical symptoms are less likely to be induced. Therefore, we designed a protocol for repetitive high-dose bronchial allergen challenges to generate clinical symptoms and airway inflammation.

Methods

A total of 27 patients aged 18 to 40 years with positive skin-prick tests and mild asthma underwent repetitive high-dose allergen challenges with household dust mites for four consecutive days. Pulmonary function and exhaled NO were measured at every visit. Induced sputum was analysed before and after the allergen challenges for cell counts, ECP, IL-5, INF-γ, IL-8, and the transcription factor Foxp3.

Results

We found a significant decrease in pulmonary function, an increased use of salbutamol and the development of a late asthmatic response and bronchial hyperresponsiveness, as well as a significant induction of eNO, eosinophils, and Th-2 cytokines. Repeated provocation was feasible in the majority of patients. Two subjects had severe adverse events requiring prednisolone to cope with nocturnal asthma symptoms.

Conclusions

Repeated high-dose bronchial allergen challenges resulted in severe asthma symptoms and marked Th-2-mediated allergic airway inflammation. The high-dose challenge model is suitable only in an attenuated form in diseased volunteers for proof-of-concept studies and in clinical settings to reduce the risk of severe asthma exacerbations.

Trial registration

ClinicalTrials.govNCT00677209

【 授权许可】

   
2012 Schulze et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Gauvreau GM, Watson RM, Rerecich TJ, Baswick E, Inman MD, O'Byrne PM: Repeatability of allergen-induced airway inflammation. J Allergy Clin Immunol 1999, 104:66-71.
• [2]Schulze J, Rosewich M, Dressler M, Riemer C, Rose MA, Zielen S: Bronchial allergen challenge using the medicaid dosimeter. Int Arch Allergy Immunol 2012, 157:89-97.
• [3]Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB, Boushey HA: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997, 155:1828-1834.
• [4]Gauvreau GM, Becker AB, Boulet LP, Chakir J, Fick RB, Greene WL, Killian KJ, O'byrne PM, Reid JK, Cockcroft DW: The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol 2003, 112:331-338.
• [5]Rosewich M, Rose MA, Eickmeier O, Travaci M, Kitz R, Zielen S: Montelukast as add-on therapy to beta-agonists and late airway response. Eur Respir J 2007, 30:56-61.
• [6]van Rensen EL, Evertse CE, van Schadewijk WA, van Wijngaarden S, Ayre G, Mauad T, Hiemstra PS, Sterk PJ, Rabe KF: Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 2009, 64:72-80.
• [7]Djukanović R, Feather I, Gratziou C, Walls A, Peroni D, Bradding P, Judd M, Howarth PH, Holgate ST: Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. Thorax 1996, 51:575-581.
• [8]Sulakvelidze I, Inman MD, Rerecich T, O'Byrne PM: Increases in airway eosinophils and interleukin-5 with minimal bronchoconstriction during repeated low-dose allergen challenge in atopic asthmatics. Eur Respir J 1998, 11:821-827.
• [9]Arshad SH, Hamilton RG, Adkinson NF: Repeated aerosol exposure to small doses of allergen. A model for chronic allergic asthma. Am J Respir Crit Care Med 1998, 157:1900-1906.
• [10]Roquet A, Lagging E, Ihre E, van Hage-Hamsten M, Halldén G, Härfast B, Zetterström O: No signs of activity markers in peripheral blood despite increased bronchial reactivity after repeated low-dose allergen exposure. APMIS 1998, 106:293-299.
• [11]Lensmar C, Prieto J, Dahlén B, Eklund A, Grunewald J, Roquet A: Airway inflammation and altered alveolar macrophage phenotype pattern after repeated low-dose allergen exposure of atopic asthmatic subjects. Clin Exp Allergy 1999, 29:1632-1640.
• [12]de Kluijver J, Evertse CE, Schrumpf JA, van der Veen H, Zwinderman AH, Hiemstra PS, Rabe KF, Sterk PJ: Asymptomatic worsening of airway inflammation during low-dose allergen exposure in asthma: protection by inhaled steroids. Am J Respir Crit Care Med 2002, 166:294-300.
• [13]Liu LY, Swenson CA, Kelly EA, Kita H, Jarjour NN, Busse WW: Comparison of the effects of repetitive low-dose and single-dose antigen challenge on airway inflammation. J Allergy Clin Immunol 2003, 111:818-825.
• [14]Schubert R, Kitz R, Beermann C, Rose MA, Lieb A, Sommerer PC, Moskovits J, Alberternst H, Böhles HJ, Schulze J, Zielen S: Effect of n-3 polyunsaturated fatty acids in asthma after low-dose allergen challenge. Int Arch Allergy Immunol 2009, 148:321-329.
• [15]Grainge C, Howarth PH: Repeated high-dose inhalation allergen challenge in asthma. Clin Respir J 2011, 5:150-155.
• [16]Boulet LP, Gauvreau G, Boulay ME, O'Byrne P, Cockcroft DW: The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti-inflammatory therapies. Allergy 2007, 62:1101-1110.
• [17]Rose MA, Weigand B, Schubert R, Schulze J, Zielen S: Safety, tolerability, and impact on allergic inflammation of autologous E.coli autovaccine in the treatment of house dust mite asthma - a prospective open clinical trial. BMC Complement Altern Med 2011, 3:11-45.
• [18]Brusasco V, Crapo R, Viegi G: ATS/ERS Task Force: Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
• [19]Schulze J, Rosewich M, Riemer C, Dressler M, Rose MA, Zielen S: Methacholine challenge - comparison of an ATS protocol to a new rapid single concentration technique. Respir Med 2009, 103:1898-1903.
• [20]Silkoff PE, et al.: Recommendations for standardized procedures for the online and off-line measurement of exhaled lower nitric oxide and nasal nitric oxide in adults and children –1999. The official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 1999, 1999(160):2104-2117.
• [21]Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 2001, 25:402-408.
• [22]Taylor DA, Harris JG, O'Connor BJ: Comparison of incremental and bolus dose inhaled allergen challenge in asthmatic patients. Clin Exp Allergy 2000, 30:56-63.
• [23]Wasserfallen JB, Leuenberger P: Comparison between incremental and single-dose allergen administration in bronchial provocation tests. J Asthma 1996, 33:169-178.
• [24]Bland JM, Altman DG: Applying the right statistics: analyses of measurement studies. Ultrasound Obstet Gynecol 2003, 22:85-93.
• [25]De Blay F, Krieger P, Spirlet F, Moreau L, Duvernelle C, Kassel O, Kopferschmitt MC, Gasser B, Demangeat C, Pauli G, Frossard N: Repeated inhalation of low doses of cat allergen that do not induce clinical symptoms increases bronchial hyperresponsiveness and eosinophil cationic protein levels. Int Arch Allergy Immunol 1999, 120:158-165.
• [26]Rosenthal RR, Norman PS, Summer WR: Bronchoprovocation: effect on priming and desensitization phenomenon in the lung. J Allergy Clin Immunol 1975, 56:338-346.
• [27]Moscato G, Dellabianca A, Paggiaro P, Bertoletti R, Corsico A, Perfetti L: Peak expiratory flow monitoring and airway response to specific bronchial provocation tests in asthmatics. Monaldi Arch Chest Dis 1993, 48:23-28.
• [28]Bérubé D, Cartier A, L'Archevêque J, Ghezzo H, Malo JL: Comparison of peak expiratory flow rate and FEV1 in assessing bronchomotor tone after challenges with occupational sensitizers. Chest 1991, 99:831-836.
• [29]Cockcroft DW, Ruffin RE, Dolovich J, Hargreave FE: Allergen-induced increase in non-allergic bronchial reactivity. Clin Allergy 1977, 7:503-513.
• [30]Cartier A, Thomson NC, Frith PA, Roberts R, Hargreave FE: Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. J Allergy Clin Immunol 1982, 70:170-177.
• [31]Kharitonov SA, O'Connor BJ, Evans DJ, Barnes PJ: Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide. Am J Respir Crit Care Med 1995, 151:1894-1899.
• [32]Thunberg S, Gafvelin G, Nord M, Grönneberg R, Grunewald J, Eklund A, van Hage M: Allergen provocation increases TH2-cytokines and FOXP3 expression in the asthmatic lung. Allergy 2010, 65:311-318.
• [33]Erpenbeck VJ, Hagenberg A, Krentel H, Discher M, Braun A, Hohlfeld JM, Krug N: Regulation of GATA-3, c-maf and T-bet mRNA expression in bronchoalveolar lavage cells and bronchial biopsies after segmental allergen challenge. Int Arch Allergy Immunol 2006, 139:306-316.
• [34]Liu L, Jarjour NN, Busse WW, Kelly EA: Enhanced generation of helper T type 1 and 2 chemokines in allergen-induced asthma. Am J Respir Crit Care Med 2004, 169:1118-1124.
• [35]De Monchy JG, Kauffman HF, Venge P, Koëter GH, Jansen HM, Sluiter HJ, De Vries K: Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis 1985, 131:373-376.
• [36]Pin I, Freitag AP, O'Byrne PM, Girgis-Gabardo A, Watson RM, Dolovich J, Denburg JA, Hargreave FE: Changes in the cellular profile of induced sputum after allergen-induced asthmatic responses. Am Rev Respir Dis 1992, 145:1265-1269.
• [37]Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
• [38]Hartl D, Koller B, Mehlhorn AT, Reinhardt D, Nicolai T, Schendel DJ, Griese M, Krauss-Etschmann S: Quantitative and functional impairment of pulmonary CD4 + CD25hi regulatory T cells in pediatric asthma. J Allergy Clin Immunol 2007, 119:1258-1266.
• [39]Akdis CA, Akdis M: Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 2009, 123:735-746.
• [40]Orihara K, Narita M, Tobe T, Akasawa A, Ohya Y, Matsumoto K, Saito H: Circulating Foxp3 + CD4+ cell numbers in atopic patients and healthy control subjects. J Allergy Clin Immunol 2007, 120:960-962.